Denis Lacombe

4.3k total citations · 2 hit papers
29 papers, 3.0k citations indexed

About

Denis Lacombe is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Denis Lacombe has authored 29 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Denis Lacombe's work include Glioma Diagnosis and Treatment (15 papers), Cancer Genomics and Diagnostics (11 papers) and Brain Metastases and Treatment (10 papers). Denis Lacombe is often cited by papers focused on Glioma Diagnosis and Treatment (15 papers), Cancer Genomics and Diagnostics (11 papers) and Brain Metastases and Treatment (10 papers). Denis Lacombe collaborates with scholars based in Belgium, Netherlands and France. Denis Lacombe's co-authors include Martin J. van den Bent, Thierry Gorlia, Alba A. Brandes, Martin Taphoorn, Johan M. Kros, Marc Frénay, Mathilde C.M. Kouwenhoven, Cees Tijssen, Anouk Allgeier and Winand N.M. Dinjens and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Denis Lacombe

28 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

2012 804 citations Martin J. van den Bent, Alba A. Brandes et al. Journal of Clinical Oncology profile →
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

2006 523 citations Martin J. van den Bent, Alba A. Brandes et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Denis Lacombe Belgium	15	2.5k	1.0k	948	915	494	29	3.0k
Gregory Cairncross Canada	19	3.0k 1.2×	1.4k 1.4×	679 0.7×	764 0.8×	678 1.4×	41	3.7k
Alicia Tosoni Italy	29	2.9k 1.2×	1.3k 1.2×	842 0.9×	1.1k 1.2×	799 1.6×	103	4.2k
Sumihito Nobusawa Japan	24	2.2k 0.9×	575 0.6×	1.1k 1.1×	1.3k 1.4×	314 0.6×	115	3.1k
Blandine Boisselier France	22	2.2k 0.9×	571 0.6×	1.1k 1.2×	1.2k 1.3×	577 1.2×	47	2.9k
Judith W. M. Jeuken Netherlands	26	2.1k 0.8×	577 0.6×	1.3k 1.4×	1.4k 1.6×	433 0.9×	47	3.1k
Karen Fink United States	31	3.5k 1.4×	1.4k 1.3×	1.1k 1.2×	1.6k 1.7×	563 1.1×	73	4.7k
Ralf Ketter Germany	18	1.7k 0.7×	743 0.7×	589 0.6×	683 0.7×	345 0.7×	49	2.5k
Jörg Balß Germany	11	2.1k 0.8×	433 0.4×	1.2k 1.3×	1.1k 1.2×	469 0.9×	12	2.7k
Jochen Meyer Germany	22	2.8k 1.1×	1.3k 1.3×	1.4k 1.4×	1.7k 1.8×	466 0.9×	43	4.6k
B. Ahmed Rasheed United States	4	2.9k 1.1×	771 0.7×	1.9k 2.0×	1.9k 2.1×	706 1.4×	5	4.4k

Countries citing papers authored by Denis Lacombe

Since Specialization

Citations

This map shows the geographic impact of Denis Lacombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Lacombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Lacombe more than expected).

Fields of papers citing papers by Denis Lacombe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Lacombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Lacombe. The network helps show where Denis Lacombe may publish in the future.

Co-authorship network of co-authors of Denis Lacombe

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Lacombe. A scholar is included among the top collaborators of Denis Lacombe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Lacombe. Denis Lacombe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Graaf, Winette T.A. van der, S.M. Keller, Jean‐Yves Blay, et al.. (2025). Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action. Cancer Treatment Reviews. 140. 103013–103013.

Marinus, A., et al.. (2022). How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer. Frontiers in Pharmacology. 13. 969778–969778. 8 indexed citations

Lacombe, Denis, et al.. (2021). Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer. European Journal of Cancer. 151. 221–232. 8 indexed citations

Pilette, Charles, Christopher E. Brightling, Denis Lacombe, & Guy Brusselle. (2018). Urgent need for pragmatic trial platforms in severe asthma. The Lancet Respiratory Medicine. 6(8). 581–583. 11 indexed citations

Lacombe, Denis, et al.. (2018). Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. Frontiers in Medicine. 5. 6–6. 14 indexed citations

Negrouk, Anastassia, Denis Lacombe, Fátima Cardoso, et al.. (2017). Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. ESMO Open. 2(3). e000187–e000187. 9 indexed citations

Law, Kate, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 7. ed20–ed20. 6 indexed citations

Kros, Johan M., Aurelio Hernández‐Laín, Gianluca Marucci, et al.. (2015). Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Journal of Clinical Oncology. 33(17). 1943–1950. 12 indexed citations

Baumert, Brigitta G., Warren Mason, Gail Ryan, et al.. (2013). Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033).. Journal of Clinical Oncology. 31(15_suppl). 2007–2007. 30 indexed citations

10.

Gorlia, Thierry, Jean‐Yves Delattre, Alba A. Brandes, et al.. (2013). New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer. 49(16). 3477–3485. 48 indexed citations

11.

Bent, Martin J. van den, Alba A. Brandes, Martin Taphoorn, et al.. (2012). Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology. 31(3). 344–350. 804 indexed citations breakdown →

12.

Bady, Pierre, Davide Sciuscio, Jocelyne Bloch, et al.. (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica. 124(4). 547–560. 221 indexed citations

13.

Blay, Jean‐Yves, Denis Lacombe, Françoise Meunier, & Roger Stupp. (2012). Personalised medicine in oncology: questions for the next 20 years. The Lancet Oncology. 13(5). 448–449. 10 indexed citations

14.

Lalami, Yassine, Pol Specenier, Ahmad Awada, et al.. (2012). EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiotherapy and Oncology. 105(2). 238–240. 11 indexed citations

15.

Gorlia, Thierry, Roger Stupp, Alba A. Brandes, et al.. (2012). New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer. 48(8). 1176–1184. 146 indexed citations

16.

Bent, Martin J. van den, Hendrikus J. Dubbink, Yannick Marie, et al.. (2010). IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research. 16(5). 1597–1604. 304 indexed citations

17.

Trimble, Edward L., Jeffrey S. Abrams, Ralph M. Meyer, et al.. (2009). Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology. 27(30). 5109–5114. 35 indexed citations

18.

Kouwenhoven, Mathilde C.M., Thierry Gorlia, Johan M. Kros, et al.. (2009). Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro-Oncology. 11(6). 737–746. 63 indexed citations

19.

Bent, Martin J. van den, Hendrikus J. Dubbink, Marc Sanson, et al.. (2009). MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology. 27(35). 5881–5886. 202 indexed citations

20.

Hildebrand, Jerzy, Thierry Gorlia, Johan M. Kros, et al.. (2008). Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). European Journal of Cancer. 44(9). 1210–1216. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact